Treating AML, Before and After Relapse

Treating AML, Before and After Relapse

Author: American Society of Hematology June 18, 2026 Duration: 16:13

In this episode, Blood editor Dr. Laura Michaelis interviews Drs. Nigel Russell and Uwe Platzbecker on their articles published in volume 147 issue 10 of Blood. Dr. Russell discuses "CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non–adverse-risk AML: the NCRI AML18 trial" where a large randomized trial demonstrated that DA-GO2 provided greater overall survival as compared to CPX-351, and that further studies should compare DA-GO2 to lower-intensity venetoclax-based regimens. Dr. Platzbecker shares insights from the first prospective study to evaluate the clinical impact of early therapeutic intervention for MRD in "Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial" demonstrating potential therapies for patients to achieve and maintain remission.


Produced by the American Society of Hematology, the Blood Podcast serves as an audio companion to the groundbreaking research found in its namesake journal. Each episode delves into the latest published studies, translating complex findings on blood disorders, cancers, and immune system functions into accessible discussions. You'll hear directly from the researchers and clinicians who are shaping the field, as they break down their methodologies, interpret results, and explore the real-world implications for patient care. This isn't just a summary; it's a critical conversation that examines the how and why behind the science, offering context that the printed page alone cannot provide. Whether you're a practicing hematologist, a trainee in the field, or simply fascinated by the intricate world of human biology, this podcast provides a vital stream of knowledge. It connects the dots between laboratory discovery and clinical practice, all while exploring topics that span from foundational biology to cutting-edge therapeutic advances. Tune in for a thoughtful analysis that makes the latest hematology research comprehensible and immediately relevant to your work or curiosity.
Author: Language: English Episodes: 50

Blood Podcast
Podcast Episodes
Dose Makes the Cure: Venetoclax in Ph- ALL [not-audio_url] [/not-audio_url]

Duration: 14:21
In this week's episode, Blood editor Dr. James Griffin interviews Dr. Jianxiang Wang from the National Clinical Research Center for Blood Diseases and the Institute of Hematology and Blood Diseases Hospital, Chinese Acad…
MYB driven ALL and Venetoclax-Azacitidine damage to Bone Marrow [not-audio_url] [/not-audio_url]

Duration: 24:34
In this week's episode, Blood editor Dr. James Griffin interviews Drs. Thomas Milne and Dominique Bonnet on their latest articles published in volume 147 issue 24 of Blood. Dr. Milne discusses how transcription factors s…
Predictive Markers of Glofitamab Resistance in R/R B-NHL [not-audio_url] [/not-audio_url]

Duration: 15:41
In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Camille Laurent and Christine Bezombes on their latest article published in Blood titled "Patient-derived lymphoma spheroids reveal predictive markers…
FLT3-ITD microclones in AML and Results from the RESET-PV trial [not-audio_url] [/not-audio_url]

Duration: 13:48
In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Pierre-Yves Dumas and Samik Basu on their latest articles published in Blood. Dr. Dumas talks about "Prognostic impact of FLT3-ITD microclones in y…
Initial CHORUS data on HHT and ASH HematOmics Program [not-audio_url] [/not-audio_url]

Duration: 26:14
In this week's episode, Blood editor Dr. James Griffin interviews Drs. Hanny Al-Samkari and Xin Zhou on their latest articles published in Blood. This episode highlights two important advances in hematology: the first re…